Actionable insights straight to your inbox


“Ingestible Therapy Activator System and Method” in Patent Application Approval Process

By a News Reporter-Staff News Editor at Drug Week -- A patent application by the inventors ZDEBLICK, MARK (Portola Valley, CA); JENSEN, MARC (Los Gatos, CA); COLLIOU, OLIVIER (Los Gatos, CA);

By a News Reporter-Staff News Editor at Drug Week — A patent application by the inventors ZDEBLICK, MARK (Portola Valley, CA); JENSEN, MARC (Los Gatos, CA); COLLIOU, OLIVIER (Los Gatos, CA); STRAND, ANGELA (Portland, OR), filed on February 26, 2014, was made available online on July 3, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents (see also Proteus Digital Health, Inc.).
This patent application is assigned to Proteus Digital Health, Inc.
The following quote was obtained by the news editors from the background information supplied by the inventors: “Multiple therapies exist for various health-related conditions, events, and defects. Such therapies may be implemented as implanted devices, e.g., cardiac rhythm management devices, neural stimulation/neuromodulation devices, intrathecal drug delivery pumps, and functional neuromodulation prostheses such as cochlear implants, retinal implants, and artificial joints, limbs and organs. Once implanted, however, such devices may not provide the functionality to facilitate controlled activation or modification.
“In one example, a neural stimulation device may deliver pain-control therapies to the spinal column, yet the neural stimulation device may not be activated on demand. Stated differently, the neural stimulation device is always activated after implantation. As a result, the patient may be subjected to neural stimulation, as well as its associated unwanted side effects, at times when such therapy is not needed.
“In another example, a neural modulation device such as a spinal cord stimulator may provide therapeutic benefit for pain, yet the rate of stimulation may not be adjustable to align stimulation to the patient’s lifestyle, e.g., a higher intensity during high activity periods and a lower intensity during low activity periods. As a result, the patient may need to restrict activities which do not conform to the stimulation intensity to receive optimal therapy results or suffer diminished therapy results when engaged in non-conforming activities.
“Therefore, it would be desirable to have systems, devices, and methods for controlling therapies, for optimizing therapy results, and for enhancing patient treatment without having limitations placed on the patient.”
In addition to the background information obtained for this patent application, NewsRx journalists also obtained the inventors’ summary information for this patent application: “The present disclosure includes a system for providing instructions to a therapeutic device. The therapeutic device can be any type of device, such as a cardiac therapeutic device, a neural stimulation device, an intrathecal drug delivery pump, a gastrointestinal device; and a neural stimulation prosthesis. The system includes an ingestible unit and a responder module. The ingestible unit includes an output or effector module that provides an effector instruction to the responder module. The responder module receives and processes the effector instruction and communicates the effector instruction to the therapeutic device to alter the operation of the therapeutic device.
“FIG. 1 illustrates an ingestible activator environment including an ingestible therapy activator.
“FIG. 2 illustrates the ingestible therapy activator of FIG. 1 in greater detail.
“FIG. 3 illustrates an ingestible device of the therapy activator of FIG. 2 in greater detail.
“FIG. 4 illustrates an effector module of the ingestible device of FIG. 3 in greater detail.
“FIG. 5 illustrates an effector instruction of the ingestible therapy activator of FIG. 2 in greater detail.
“FIG. 6 illustrates a responder module of the ingestible therapy activator of FIG. 2 in greater detail.
“FIG. 7 illustrates a therapeutic device of the ingestible activator environment of FIG. 1.
“FIG. 8 illustrates ingestion and activation of a therapeutic device via an ingestible therapy activator.”
URL and more information on this patent application, see: ZDEBLICK, MARK; JENSEN, MARC; COLLIOU, OLIVIER; STRAND, ANGELA. Ingestible Therapy Activator System and Method. Filed February 26, 2014 and posted July 3, 2014. Patent URL:\%2Fnetahtml\%2FPTO\%2Fsearch-adv.html&r=1836&p=37&f=G&l=50&d=PG01&S1=20140626.PD.&OS=PD/20140626&RS=PD/20140626
Keywords for this news article include: Therapy, Cardiology, Proteus Digital Health Inc..
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

Many of us economy-watchers have been expecting recession, though with significant differences on odds and timing. Regardless, recent banking developments just made recession more likely and may have accelerated its onset.
Many people think of position size in terms of how many shares they own of a particular stock. But it’s much smarter to think of it in terms of what percentage of your total capital is in a particular stock.